Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthrit...

ver descrição completa

Detalhes bibliográficos
Autor principal: Reginster, Jean Yves (author)
Outros Autores: Cooper, Cyrus (author), Hochberg, Marc (author), Pelletier, Jean Pierre (author), Rizzoli, René (author), Kanis, John (author), Abadie, Eric (author), Maheu, Emmanuel (author), Brandi, Maria Luisa (author), Devogelaer, Jean Pierre (author), Branco, Jaime (author), Herrero-Beaumont, Gabriel (author), D'Hooghe, Pieter (author), Bruyère, Olivier (author)
Formato: review
Idioma:eng
Publicado em: 2022
Assuntos:
Chondroitin
Glucosamine
Hyaluronic acid
Osteoarthritis
Symptomatic slow-acting drugs in osteoarthritis
Medicine(all)
Texto completo:http://hdl.handle.net/10362/142323
País:Portugal
Oai:oai:run.unl.pt:10362/142323

Texto Completo

http://hdl.handle.net/10362/142323

Registos relacionados